All In Biotech

Drug Trial Radar · NCT05870748

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

600

Actual

Start

Jul 12, 2023

Primary completion

Aug 26, 2025

Study completion Aug 26, 2025

Sponsor

Lead sponsor
Sutro Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); Asia-Pacific Gynecologic Oncology Trials Group; GOG Foundation
First posted
May 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Conditions

  • Ovarian Cancer
  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • Platinum-resistant Ovarian Cancer

Interventions

  • Luveltamab tazevibulinDrug

    Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.

  • PegfilgrastimDrug

    Pegfilgrastim or pegylated G-CSF is approved and used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. It increases the proliferation and differentiation of neutrophils.

  • GemcitabineDrug

    Gemcitabine is a chemotherapy regimen used for treating platinum-resistant ovarian cancer. It inhibits ribonucleotide reductase and DNA polymerase, hindering tumor cell growth and promoting cell death.

  • PaclitaxelDrug

    Paclitaxel is a chemotherapy regimen approved for treatment of previously treated ovarian cancer. It stabilizes microtubules, inhibiting tumor cell replication.

  • Pegylated liposomal doxorubicinDrug

    Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.

  • TopotecanDrug

    Topotecan is a chemotherapy regimen approved for treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. It binds to topoisomerase I inducing DNA breaks and subsequent tumor cell apoptosis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: up to 24 months
  2. Objective Response Rate (ORR)Time frame: up to 24 months

Locations

63 sites in 7 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC-Hope

    Tucson, Arizona

  • Sutter Health

    Daly City, California

  • Scripps Health

    San Diego, California

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Baptist Health South Florida (BHSF) - Miami Cancer Institute

    Miami, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • USF Research & Innovation

    Tampa, Florida

  • Augusta University Medical Center

    Augusta, Georgia

  • Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler

    Savannah, Georgia

  • Sinai Hospital of Baltimore

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • Minnesota Oncology Hematology

    Minneapolis, Minnesota

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Optimum Clinical Research Group

    Albuquerque, New Mexico

  • NYU Langone Health

    New York, New York

  • Good Samaritan Hospital Medical Center

    West Islip, New York

  • Pitt County Memorial Hospital, Inc. ECU Medical Center

    Greenville, North Carolina

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Miami Valley Hospital South

    Centerville, Ohio

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Ohio State University Center

    Columbus, Ohio

  • Kettering Health

    Kettering, Ohio

  • ProMedica Flower Hospital

    Sylvania, Ohio

  • Oklahoma Cancer Specialists and Research Institute- Tulsa Cancer Center

    Tulsa, Oklahoma

  • Oncology Associates of Oregon, PC

    Eugene, Oregon

  • Providence Gynecologic Oncology Clinic

    Portland, Oregon

  • Lancaster General Hospital

    Lancaster, Pennsylvania

  • Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Oncology

    Dallas, Texas

  • Texas Oncology-DFW

    Dallas, Texas

  • Texas Oncology-San Antonio

    San Antonio, Texas

  • Baylor Scott & White Medical Center - Temple (Temple Clinic)

    Temple, Texas

  • Texas Oncology - The Woodlands

    The Woodlands, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Virginia Mason Medical Center - Digestive Disease Institute - Liver Center

    Seattle, Washington

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.